ERAS/ 10/16/2025 · 9:13 AM Erasca Stock Gets Buy Rating: Analyst Sees Huge Potential in Cancer Drug Stifel initiates Erasca coverage with Buy rating and $4 target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition.